Podcasts about Metastatic breast cancer

I am grateful to have Dr. Shabana Dewani join me for this conversation.The words “stage IV breast cancer” can bring an enormous amount of fear.But fear is often made worse by uncertainty and misconceptions.In Part 1 of our special three-part series on metastatic breast cancer, we go back to the basics: What exactly is metastatic breast cancer? How is it different from early-stage disease? Where can breast cancer spread? And what does a metastatic diagnosis really mean for someone's life and future?We also address some of the most common myths surrounding stage IV disease—including the belief that there are no treatment options or that someone with metastatic breast cancer will always look or feel sick.While metastatic breast cancer remains a serious diagnosis, treatment has evolved tremendously. Care is increasingly personalized to the biology of the cancer, with the goals of controlling disease, helping patients live longer, preserving quality of life, and managing symptoms.Most importantly, we talk about something every patient deserves from their medical team:Honesty and hope can exist together.If you or someone you love has recently been diagnosed with metastatic breast cancer, you do not need to have all the answers today.You are more than a stage.You are more than a scan.And you are not alone.We are both grateful to have conversations that elevate awareness and strengthen our community.Dr. Shabana Dewani  is board certified in Medical Oncology, Hematology, and Internal Medicine—and a joy to listen to!  She breaks down the oncology process and important factors when deciding treatment.  You'll be able to hear her passion for helping others ensuring they get the best treatment possible.Stay Connected with Dr. Deepa Halaharvi:TikTok: @breastdoctorInstagram: @drdhalaharviTBCP Instagram: @thebreastcancerpodcastWebsite: https://drdeepahalaharvi.com/YouTube: https://www.youtube.com/@deepahalaharvi5917Instagram: @thebreastcancerpodcast

Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics: Introduction (00:00) Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45) Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00) Strategies to Prevent and Manage Hyperglycemia (27:02) Clinical Utility of Capivasertib for HR-Positive mBC (38:09) Mitigation and Management of Gastrointestinal Adverse Events (51:05) Management of Dermatologic Adverse Events (59:58) Potential Role of Gedatolisib in the Management of HR-Positive mBC (1:08:42) Monitoring and Management of Cytopenias (1:21:23) CME information and select publications

New data and broad indications for trastuzumab deruxtecan are changing the paradigm for HER2-positive early breast cancer. Listen to Shanu Modi, MD, and Sara A. Hurvitz, MD, FACP, discuss how they are incorporating these changes into clinical practice in the neoadjuvant, adjuvant, and possibly metastatic settings. Presenters: Sara A. Hurvitz, MD, FACP Professor of Medicine Smith Family Endowed Chair in Women's Health Senior Vice President, Clinical Research Division Fred Hutch Cancer Center Head, Division of Hematology/Oncology, Department of Medicine University of Washington School of Medicine Seattle, Washington Shanu Modi, MD Section Head, HER2 Breast Program Professor and Attending Member Breast Medicine Service, Department of Medicine Memorial Sloan Kettering Cancer Center Weill Cornell Medical College New York, New York Link to full program: https://bit.ly/4z1Xb6a Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate web of scientific advancements, regulatory updates, and strategic maneuvers shaping the industry. Let's begin with Eli Lilly's impressive financial performance, clocking a record-breaking $23 billion in revenue for Q2 2023. This achievement, driven by the success of Mounjaro and Zepbound in metabolic diseases, underscores the competitive landscape of therapies targeting chronic conditions. However, the slower launch of Foundayo highlights ongoing challenges. Meanwhile, competition in obesity treatments is intensifying as Novo Nordisk's Wegovy continues to dominate despite new entrants like Eli Lilly's Foundayo. This scenario reflects growing patient preference for oral medications over injectables. Gilead Sciences' HIV prevention franchise has exceeded $1 billion in quarterly sales, reflecting an increasing reliance on effective small molecule therapies for infectious diseases. Gilead also remains a focal point with its HIV pre-exposure prophylaxis franchise reaching sales milestones amid legal victories defending their tenofovir-based treatments. These legal precedents could influence future innovation policies across the industry. Artificial intelligence continues to make waves in drug discovery and clinical trials. Icon's partnership with Anthropic aims to integrate AI capabilities to accelerate drug development timelines. Similarly, Phylo and Chugai Pharmaceutical are collaborating to optimize drug discovery workflows using advanced AI platforms. These collaborations highlight a strategic move towards enhancing efficiency in drug development processes. In oncology, Amplia Therapeutics and Eli Lilly are evaluating a combination therapy for non-small cell lung cancer, while Evexta Bio and Roche are exploring a joint study for metastatic breast cancer. These partnerships underscore the industry's focus on combination therapies and precision medicine to improve cancer treatment outcomes. Additionally, AstraZeneca's partnership with CSPC Pharmaceutical to enhance biologics manufacturing in China signifies the importance of localized production capabilities. On the regulatory front, Arrowhead Pharmaceuticals' acquisition of an FDA rare pediatric disease priority review voucher for Plozasiran represents a commitment to addressing unmet needs in rare diseases. This voucher could expedite new drug applications, potentially bringing life-saving treatments to patients more quickly. Despite these advancements, challenges persist. Novo Nordisk's Cagrisema failed to achieve its primary endpoint in a Phase 3 trial for type 2 diabetes, highlighting the complexities of developing combination therapies for metabolic disorders. Similarly, Eli Lilly's discontinuation of its Phase 1/2 trial for GBA1 gene therapy reflects the hurdles faced in advancing gene therapies. Looking at industry dynamics, Amgen's decision to discontinue its early-stage obesity drug signifies a strategic shift towards focusing on more promising pipeline candidates like Maritide. This move aligns with broader trends prioritizing candidates with significant potential impact on patient care. Amgen's 'Repatha' is experiencing renewed interest due to positive cardiovascular risk reduction data, showcasing how robust clinical results can rejuvenate existing products. In regulatory news, Merck's 'Lipfendra' has been spotlighted by the FDA as part of its Complex New Product Validation pilot program. This positions Lipfendra as a potential game-changer in the PCSK9 inhibitor category. Lastly, financial maneuvers such as Attovia Therapeutics' $289 million IPO and Expedition Therapeutics' $115 million Series B funding highlight investor confidence in novel therapeutic areas like dermatological and respiratory treatments. The pharmaceutical landscape remains dynamic with Johnson & Johnson investing heavily in gene therapy ventures like Sail Biomedicines for CAR-T therapies. Meanwhile, regulatory challenges persist as seen with Capricor's cell therapy setback due to statistical complexities during FDA reviews. Despite setbacks faced by some companies, innovations continue to thrive. The launch of personalized genetic therapy centers signals a shift towards individualized medicine while research into safer CAR-T therapies progresses. In conclusion, these developments reflect an industry driven by innovation amidst regulatory challenges and strategic adjustments. As companies navigate this evolving landscape, their decisions will shape future healthcare innovations and patient care outcomes. Thank you for joining us on Pharma Daily; stay tuned for more insights from the world of pharmaceuticals and biotech.Support the show

Love the podcast? Send us a text!What does life really look like five—or even ten—years after a metastatic breast cancer diagnosis?For many people, the initial diagnosis is filled with uncertainty, fear, and countless unanswered questions. But thanks to advances in treatment, more people are living longer with metastatic breast cancer than ever before, and with that comes an important conversation about what it means to continue living while navigating an incurable disease.In this episode of Breast Cancer Conversations, host Laura Carfang is joined by Paula Bouckhuyt and Teresa Noah, two women who share their personal experiences living with metastatic breast cancer for more than five years.Together, they discuss how life has evolved since diagnosis, the realities of long-term treatment, scan anxiety, relationships, work, disability, palliative care, and finding hope in the midst of uncertainty.In this episode, we discuss: What it's like living with metastatic breast cancer for five and ten years  How treatment routines become part of everyday life  Scan anxiety and coping with uncertainty  The emotional impact of long-term survivorship with MBC  Living with oral therapies like Xeloda and Ibrance  How relationships change after an MBC diagnosis  Why support groups can make a profound difference  The role of palliative care in improving quality of life  Mental health, resilience, and asking for help  Advice for those newly diagnosed with metastatic breast cancer This episode reminds us that while every metastatic breast cancer journey is different, there is no single way to live with this disease. Through honest conversation, Paula and Teresa offer hope, perspective, and practical wisdom for anyone navigating life with MBC.Support the showListener FeedbackIf this episode resonated with you, we invite you to leave a review on Apple Podcasts or Spotify.You can also click the link in the show notes that says "Love this episode? Send us a text" to share feedback.Messages are completely anonymous.If you would like us to follow up directly, please include your email address in your message so we can respond.Latest News: Join our Mailing List - New content drops every Monday! Discover FREE programs, support groups, and resources from SurvivingBReastCancer.org! Become a Breast Cancer Conversations+ Member! Sign Up Now. Enjoying our content? Please consider supporting our work. 

For many families, cancer doesn't affect just one person. It can shape generations.⁣ When a parent is diagnosed with cancer, children often carry more than memories. They may inherit questions, uncertainty, increased risk, and life-changing decisions of their own.⁣ ⁣ In this conversation, Ashley Dedmon shares her experience of losing her mother to metastatic breast cancer, learning she carried the BRCA2 gene mutation, and ultimately making the decision to undergo a preventive mastectomy.⁣ ⁣ Together, we discuss hereditary cancer risk, genetic testing, prevention, family planning, and how understanding your family history can empower you to make informed decisions for yourself and future generations.⁣ Ashley also shares how her personal experience inspired her work as a national public health leader, patient advocate, and children's book author helping families navigate conversations about cancer and family health history.⁣ ⁣ Most importantly, this episode is a reminder that while we cannot change our family history, we can make informed decisions that help shape what comes next.⁣ ⁣ Resources Mentioned in This Episode:⁣ ⁣ To learn more about Ashley Dedmon's work, follow her on Instagram at @PinkLegacy5050 and explore her children's books, The Big Discovery and The Big Family Trip, which help families navigate conversations about cancer and family health history.⁣ ⁣ For additional education and support, visit Living Beyond Breast Cancer (LBBC) or follow @LivingBeyondBC on Instagram.⁣ ⁣ The information shared on Dear Cancer, I'm Beautiful is for educational and informational purposes only and is not intended as medical advice. Always consult your physician or qualified healthcare provider regarding your individual medical care and treatment decisions. The views and opinions expressed by guests are their own and do not necessarily reflect those of Cancer Fashionista.

Listen in to learn from Thomas Bachelot, MD, PhD, and Mafalda Oliveira, MD, PhD, about recent advances and the integration of anti-TROP2 antibody-drug conjugates (ADCs) into the management of patients with triple-negative breast cancer, including as first-line therapy for those who are not eligible for immunotherapy. Experts will cover: The evolving role of TROP2-directed antibody-drug conjugates (ADCs), including sacituzumab govitecan and datopotamab deruxtecan, in addressing unmet needs in the frontline treatment of TNBC.  Treatment sequencing, reimbursement barriers to recent approvals, and toxicity-informed treatment selection considerations. How to monitor and manage ocular and pulmonary toxicities and care-team readiness for implementing ADC-based therapy in routine practice. Presenters:Thomas Bachelot, MD, PhD Medical Oncology Department of Oncology Léon Bérard Center Lyon, France Mafalda Oliveira, MD, PhD Senior Consultant Medical Oncology Department Vall d'Hebron University Hospital Senior Clinical Investigator Breast Cancer Group Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona, Spain Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Visit the program page for more content associated with this discussion. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Featuring an interview with Prof Dr Sibylle Loibl, including the following topics: Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00) Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35) Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01) Targeting the PI3K signaling pathway in HER2-positive mBC (11:08) Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung disease (13:53) Optimal duration of and therapeutic partner for T-DXd as first-line maintenance therapy for patients with HER2-positive mBC (20:44) Case: A woman in her early 40s with metastatic relapse of HER2-positive breast cancer 2 years after completing neoadjuvant and adjuvant therapy (26:54) Role of exercise and weight control in the management of breast cancer; effect of pregnancy on the breast tumor immune environment (40:03) CME information and select publications

Featuring a slide presentation and related discussion from Prof Dr Sibylle Loibl, including the following topics: ·      Overview of the changing landscape of treatment for patients with HER2-positive metastatic breast cancer (mBC) (0:00) ·      Results from the CLEOPATRA, PATINA and HER2CLIMB-05 trials of first-line treatment and maintenance approaches for HER2-positive mBC (5:26) ·      Efficacy and safety findings from the Phase III DESTINY-Breast09 trial comparing trastuzumab deruxtecan with or without pertuzumab to taxane/trastuzumab/pertuzumab as first-line therapy for HER2-positive mBC (14:56) ·      Predictors of long-term benefit from first-line treatment with HER2-targeted agents; contribution of pertuzumab to the efficacy of first-line HER2-targeted combination regimens (22:57) ·      Control of brain metastases and CNS disease with first-line HER2-targeted regimens (26:31) CME information and select publications

Highlights from the PER® CME activity "Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2− Metastatic Breast Cancer–What the Latest Data Really Tell Us" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Virginia Kaklamani, MD, DSc; Kamel Abou Hussein, MD; Javier Cortés, MD, PhD; and Seth A. Wander, MD, PhD, discuss American Society of Clinical Oncology (ASCO) 2026 updates about data for oral selective estrogen receptor degraders (SERDs) to treat metastatic, HR-positive breast cancer.Earn CME credit by completing the full accredited activity (available through June 29, 2027): https://www.gotoper.com/courses/oncology-town-hall-updates-from-chicago-oral-serds-in-hrher2-metastatic-breast-cancerwhat-the-latest-data-really-tell-us This podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Stemline Therapeutics, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs) (2:07) Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23) Currently Available ADCs for Gynecologic Cancer Management (26:37) Currently Available ADCs for Lung Cancer Management (44:07) Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55) Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07) Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01) NCPD information and select publications  

Listen in to learn from Cristina Saura Manich, MD, PhD and Giampaolo Bianchini, MD about practical approaches to PI3K pathway testing, PI3K/AKT-targeted treatment options, and endocrine-based sequencing in metastatic breast cancer. Presenters: Cristina Saura Manich, MD, PhD Head, Breast Cancer Unit Medical Oncology Service Vall d'Hebron University Hospital Breast Cancer Program, Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Spain Giampaolo Bianchini, MD Associate Professor, Universita Vita-Salute San Raffaele Head, Breast Cancer Group, Department of Medical Oncology Head, Clinical Translational and Immunotherapy Research IRCCS Ospedale San Raffaele Milan, Italy Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Visit the program page for more content associated with this discussion.https://bit.ly/4p6W8gP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Gillian Burles was 39 years old when her breast cancer metastasized to her spine — so severely that her T10 vertebra had to be replaced with a titanium alloy cage. She was living in the Northwest Territories, 1,500 kilometers from the nearest major cancer center, with two young children at home. Her oncologist gave her 18 to 24 months.That was 20 years ago.In this conversation, Gillian talks about what it actually looked like to rebuild her life after that diagnosis — returning to work, raising her kids, completing the Camino de Santiago with her husband, and managing HER2+ metastatic breast cancer from a small city in Northern Canada. She also shares the mantra that has stayed with her since the beginning: averages are the abstraction, variation is the reality. If you're newly diagnosed and struggling to see past the statistics, this one is worth your time.Heather was diagnosed with metastatic breast cancer at 26 and has now been living with the disease for more than 25 years. Through this podcast she shares perspective, lived experience, and conversations that help people navigate life with metastatic cancer.Sensational Survivor SeriesIf you have been living with metastatic breast cancer for 10 years or more and would like to share your story on the podcast, you can apply here:https://forms.gle/6H9K7NXMAeN1QEv87Digital Guideshttps://shop.heatherjose.com/all-guides/Listener QuestionsHave a question you'd like answered in a future episode? Submit it through the contact form:https://heatherjose.comConnect with HeatherInstagram: https://instagram.com/heatherbjoseWebsite: https://heatherjose.comMusicIntro and outro music for the podcast was created by Heather's son, Ty. You can find his music here:Instagram: https://instagram.com/tyjosee

Melissa Rausch of Simi Valley, California, was diagnosed in 2019 with triple-positive breast cancer, one of the more aggressive types, and did everything her doctors told her to do. She endured 16 weeks of hard chemo, hospitalizations, a lumpectomy with unclear margins, and radiation with severe side effects. Then in November 2020, the cancer spread to her bones and her oncologist said the word she wasn't ready to accept: terminal. Instead of giving up, Melissa said "with all due respect" and started knocking on other doors. She dove into books, found holistic practitioners, overhauled her diet overnight, and eventually connected with Chris Wark's Square One program and the Healing Strong community. Through a dual path of faith, integrative care, and persistent self-advocacy, including fighting her own oncologist to return to a treatment that had actually worked. Melissa is now in complete remission. She co-founded and now leads the HealingStrong group in Simi Valley, praying for each member by name daily.HealingStrong's mission is to educate, equip and empower our group leaders and group participants through their journey with cancer or other chronic illnesses, and know there is HOPE. We bring this hope through educational materials, webinars, guest speakers, conferences, community small group support and more.Please take advantage of our FREE resources below to help you along your health and healing journey:Support Group DirectoryHolistic Curriculum - Participant GuideSupport Our Mission - DonateAdditional Health ResourcesListen to Previous EpisodesWebsite: healingstrong.org

At the Living Beyond Breast Cancer 2026 Conference on Metastatic Breast Cancer, five members of the Breastcancer.org metastatic virtual support groups shared what they'd tell someone who's just been diagnosed with metastatic breast cancer. They talked to us about the importance of having hope allowing yourself to grieve, seeking out support, and knowing that you're never alone.

In this podcast, experts Hope S. Rugo, MD, FASCO; Fabrice André, MD, PhD; Nadia Harbeck, MD; and Heather McArthur, MD, MPH; discuss updates from the SERENA-6, evERA, PREcoopERA, and TRAK-ER trials of oral selective estrogen receptor degraders (SERDS) in patients with hormone receptor–positive/HER2-negative (HR+/HER2–) early, advanced, and metastatic breast cancer (MBC). These results were presented at European Society for Molecular Oncology (ESMO) Breast 2026.

Featuring perspectives from Dr Sara A Hurvitz and Dr Virginia Kaklamani, including the following topics: Introduction: Which Biomarkers and When (0:00) Optimizing First-Line Therapy for Patients with Hormone Receptor (HR)-Positive Metastatic Breast Cancer (mBC) (5:31) SERENA-6 Trial (19:44) Inavolisib (23:08) Management of HR-Positive mBC Progressing on a CDK4/6 Inhibitor and Endocrine Therapy (31:46) Selective Estrogen Receptor Degraders (41:15) AKT (46:13) CME information and select publications

At just 26 years old, Emily Harrison Suhr found a lump in the shower and within weeks was diagnosed with stage 3 breast cancer. Nearly a decade later, she is living with metastatic breast cancer and confronting the realities of a terminal illness that few people talk about openly. In this episode, Emily shares the truth about what cancer has taken from her, and what it hasn't. From early menopause and financial stress to intimacy, marriage and navigating other people's expectations, she speaks candidly about the challenges of living with a disease that has no cure. Emily is breaking down misconceptions and creating space for honest conversations about mortality, relationships and resilience. This is a powerful discussion about life, love and finding joy in the face of uncertainty. GET IN TOUCH Sign up to the Well Newsletter to receive your weekly dose of trusted health expertise without the medical jargon. Email here or leave us a voice note here. Ask The Doc: Ask us a question in The Waiting Room. Follow us on Instagram and Tiktok. Support independent women’s media by becoming a Mamamia subscriber CREDITS Host: Dr Mariam Guest: Emily Harrison-Suhr Senior Producer: Tahli Blackman Executive Producer: Grace Rouvray Group Executive Producer: Ilaria Brophy Audio Producer: Scott Stronach Social Producer: Elly Moore Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on.Information discussed in Well. is for educational purposes only and is not intended to provide professional medical advice. Listeners should seek their own medical advice, specific to their circumstances, from their treating doctor or health care professional.Support the show: https://www.mamamia.com.au/mplus/See omnystudio.com/listener for privacy information.

In today's episode, we welcomed Pedram Razavi, MD, PhD, and Dara S. Ross, MD. Dr Razavi is a breast medical oncologist and director of Liquid Biopsy & Genomics at Memorial Sloan Kettering Cancer Center in New York, New York. Dr Ross is an associate attending pathologist at Memorial Sloan Kettering Cancer Center.In our exclusive interview, Drs Razavi and Ross discussed the evolution of ESR1 mutation–directed breast cancer management, emphasizing the role of comprehensive genomic testing at metastatic recurrence, including liquid biopsy and tissue sequencing. They highlighted that ESR1 mutations can develop in patients receiving aromatase inhibitors and that the detection of these mutations is crucial for treatment decisions. They also highlighted findings from the phase 3 SERENA-6 trial (NCT04964934), which tested switching to camizestrant upon the emergence of an ESR1 mutation during treatment with an aromatase inhibitor and a CDK4/6 inhibitor ahead of radiographic disease progression in patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Despite concerns from the FDA's Oncologic Drugs Advisory Committee (ODAC) about SERENA-6's design and overall survival outcomes, the experts praised the trial's innovative approach to personalizing breast cancer management based on biomarkers and noted ways that the ODAC decision may affect future clinical research in this field.

Love the podcast? Send us a text!In this episode of Breast Cancer Conversations, host Laura Carfang speaks with Annick Pyfferoen about her experience being diagnosed with de novo metastatic breast cancer and navigating several lines of treatment including targeted therapy, chemotherapy, a clinical trial attempt involving tumor-infiltrating lymphocytes, Enhertu, and Xeloda. She speaks openly about what it felt like to experience rapid progression and why having a plan, even one that may change, helps her navigate uncertainty.This episode is a reminder that metastatic breast cancer care is not only about what is happening on scans. It is also about communication, side effect management, informed decision-making, emotional support, and helping people live as well as possible for as long as possible. Support the showListener FeedbackIf this episode resonated with you, we invite you to leave a review on Apple Podcasts or Spotify.You can also click the link in the show notes that says "Love this episode? Send us a text" to share feedback.Messages are completely anonymous.If you would like us to follow up directly, please include your email address in your message so we can respond.Latest News: Join our Mailing List - New content drops every Monday! Discover FREE programs, support groups, and resources from SurvivingBReastCancer.org! Become a Breast Cancer Conversations+ Member! Sign Up Now. Enjoying our content? Please consider supporting our work. 

In this episode of the Breast Cancer Now podcast, returning guest Laura Ashurst shares her experience of living nearly 20 years with metastatic breast cancer.Laura speaks about why she thinks she has survived so long with a metastatic diagnosis, about the importance of holistic care and the importance of mental wellbeing. Laura talks about her advocacy for improved treatment access, the need for more consistent support, and improved data collection for those with metastatic breast cancer.  Find out more about metupUKLaura Ashurst's website Key Topics02:35 Laura's diagnoses13:40 What happened next?14:40 How it felt to be told you had 3-6 months to live18:55 Reflections on treatment and knowledge20:18 Letrozole24:27 What needs to be done for in terms of treatment for breast cancer?26:00 What Laura thinks has contributed to her survival, mental wellbeing35:35 Survivors guilt38:37 The metup UK charity40:20 The importance of improving data collection for metastatic breast cancer diagnoses 41:40 Working with Rishi Sunak44:40 What Laura is working on with metup UK46:35 The importance of signs and symptoms of metastatic breast cancer 48:45 Where do you find hope? 50:18 "I will never say I am grateful that cancer entered my life." 50:43 How Laura's metastatic breast cancer diagnosis has affected her children56:00 Advice for those diagnosed with metastatic breast cancer56:46 What should people take away from this episode? 58:20 Information on metup UK

Featuring perspectives from Dr Aditya Bardia and Dr Erica Mayer, including the following topics: Introduction: How Selective Estrogen Receptor Degraders (SERDs) Work (0:00) Second-Line Treatment for Metastatic Breast Cancer (16:01) First-Line Therapy for Metastatic Disease (33:19) Adjuvant Therapy (35:26) Toxicity, Quality of Life (47:59) New Directions (55:22) CME information and select publications

When Elissa Kalver was diagnosed with metastatic breast cancer just days before her daughter's first birthday, she was thrown into a reality no one is ever fully prepared for. Alongside the shock and fear came something many patients experience but rarely talk about: not knowing how to ask for help or what support actually looks like in real life. In this episode, Elissa shares what those early days were really like, raising a young child while navigating treatment and the emotional weight that comes with it. She opens up about the moments that felt overwhelming and the realization that there had to be a better, more human way for patients and caregivers to get the support they need. That realization led to the creation of We Got This, a first of its kind registry designed to take the guesswork out of asking for help. We discuss how the platform works and how it allows patients to request exactly what they need to make day to day life more manageable and enjoyable. This conversation highlights how "We Got This" helps patients and caregivers move beyond just getting through cancer and toward feeling supported, seen, and empowered. Elissa also shares the impact the registry is already having and what she envisions for the future, along with key takeaways from her book that offer guidance for anyone navigating cancer. This episode is for patients, caregivers, and anyone who wants to better understand how to show up in a way that truly helps.

After losing her mother to de novo metastatic breast cancer, Elise turned grief into long term advocacy and board service at The Rose. She demystifies modern metastatic care, clinical trials, and lifelong treatment while urging women of every age to push for screenings and answers. Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. 10 Key Questions Answered 1. How Elise became involved with The Rose board and metastatic breast cancer advocacy. 2. What happened during her mother’s initial breast cancer diagnosis and why it was classified as de novo metastatic. 3. How metastatic breast cancer treatment looked in the early 1990s, including bone marrow transplant approaches. 4. What key advances have changed metastatic breast cancer care since her mother’s time, such as genetic testing and subtype specific treatments. 5. How clinical trials for metastatic breast cancer usually work today and why they rarely involve placebo without treatment. 6. Why metastatic patients often need lifelong treatment and careful monitoring to stay on effective therapy as long as possible. 7. How advocacy groups and steering committees at MD Anderson direct research funds toward metastatic specific projects. 8. Why self advocacy and persistence with providers can be critical, especially for younger women seeking mammograms or additional testing. 9. How Elise balances her volunteer work, legal background, and family life while staying active on multiple boards and committees. 10. What message she wants women and families to remember about screening, self care, and not putting their own health last. Timestamped Overview 00:00 Board recruitment and early connection to The Rose02:30 High risk programs, navigation, and genetic testing03:45 Mother’s de novo metastatic diagnosis and treatment in the 1990s08:30 Limited options then versus today’s targeted therapies10:00 Role of subtyping, genetics, and clinical trials now11:30 How trials work, ongoing treatment, and progression13:00 Starting early mammograms and self advocacy in her 30s17:30 Younger women, “too young” barriers, and trusting your body21:30 Advanced breast cancer steering committee and research funding24:30 Boot Walk fundraising and metastatic specific projects28:00 Broader volunteer work and intensity of patient needs31:00 Navigation, uninsured women, and final call to advocateSee omnystudio.com/listener for privacy information.

In this podcast, experts Reshma L. Mahtani, DO; Kamel Abou Hussein, MD; and Irene Kang, MD; discuss how to translate clinical and real-world evidence regarding oral selective estrogen receptor degraders (SERDs) and targeted combination therapies into everyday clinical practice for managing hormone receptor–positive/HER2-negative metastatic breast cancer.

She was 29 years old. No family history. No warning signs. She found it herself in the shower — and it changed everything. Claire was diagnosed with breast cancer at 29, went through a lumpectomy, chemotherapy, radiation, and eight years on and off Tamoxifen — all while teaching first grade, freezing her eggs, getting married, and becoming a mom to three kids. She lived 11 and a half years of clear scans and a full, beautiful life. Then last Christmas Eve, it came back. Stage 4. Metastatic. Liver and bones. And Claire's response? "It's just a little road bump." This episode is one of the most honest, funny, and genuinely hopeful conversations about metastatic breast cancer you will ever hear. Claire is the host of Perky Bits — a blog and podcast she started in 2014 to document her journey in real time — and she holds absolutely nothing back. What we cover: Finding a golf ball-sized tumor in the shower at 29 — and what happened next How Claire worked as a first grade teacher throughout chemo and radiation Why she froze her eggs before starting chemotherapy — and had three healthy children The GI symptoms that started in July 2024 that nobody connected to cancer for months — and the critical warning signs metastatic survivors need to know Getting the call on Christmas Eve that it had spread to her liver and bones What it actually feels like when treatment starts working — and her tumors start shrinking How she talks to her young kids about her treatment without terrifying them The connection between stress and recurrence — and what she wishes she'd managed differently Why stage 4 is not what it used to be — and the women thriving 15+ years out The unexpected blessings cancer gave her — including the line she ends every speaking engagement with: "Thank you, cancer." Where Perky Bits came from — and the story of the older gentleman who had to hold her breast with gauze for an hour post-biopsy (you can't make this stuff up) Important message for every survivor: Claire's metastatic diagnosis showed up as GI symptoms — bloating, distension, constipation, diarrhea — not a breast lump. Your mammograms matter. But so does listening to your body everywhere else. Connect with Claire:https://www.instagram.com/claireperkybits/ Listen to Perkybits here: https://podcasts.apple.com/us/podcast/perkybits-riding-the-waves-of-life-intro/id1890866013?i=1000759385674 Connect with Jen: Community: Not Today Cancer — The Inner Circle GET BrocElite: Mara Labs supplements - Use code NotTodayCancer for 20% off Instagram: https://www.instagram.com/jendelvaux/ Email me: jen@jendelvaux.com

Cheri lives in Duluth, Minnesota with her adventure partner, Brent, along the stunning shores of Lake Superior. A two-time breast cancer thriver—first diagnosed with Invasive Ductal Carcinoma Stage IIIA in 2019 at 39 years old, and again with Metastatic Breast Cancer in 2021 at 41—Cheri continues to live life with strength, joy, and purpose. She leads an active, outdoor-centered lifestyle and seeks inspiration in nature, camping, fishing, hiking, and traveling. Cheri finds peace in collecting rocks, capturing her surroundings through photography, and nurturing deep connections with her family and friends. With over seventeen years of experience in the outdoor and fashion industries in leadership roles, Cheri blends her professional expertise with a B.A. in English and an M.A. in Communicating Arts to share her story through the power of writing. Cheri is a published author whose work has appeared in Wildfire Journal, the only literary magazine created for and by those "too young" for breast cancer and the Boundary Waters Journal, a nationwide wilderness canoe country magazine. Cheri is also trained as a 2026 Hear My Voice Breast Cancer Advocate with Living Beyond Breast Cancer, a national nonprofit organization providing trusted information and a community of support to those newly diagnosed, in treatment, post-treatment, and living with metastatic disease. Cheri looks to alchemize her experience into advocacy and chooses to live intentionally every day to honor her health and healing.   Resources Mentioned: Work with Laura: https://www.thebreastcancerrecoverycoach.com/health  Get The Breast Cancer Recovery Coach app: https://apps.apple.com/us/app/breast-cancer-recovery-coach/id6720763813 Learn about the Becoming You 2.0 coaching program https://www.thebreastcancerrecoverycoach.com/you Follow Cheri: https://www.instagram.com/chender1/ Episode #420 https://www.thebreastcancerrecoverycoach.com/420 Wildfire Magazine https://www.wildfirecommunity.org/ Boundary Waters journal https://www.boundarywatersjournal.com/   Let's Connect! If this episode helped you breathe a little easier, please share it with a friend or leave a review. Every share helps spread this message of hope, healing, and whole-person wellness.

In this podcast episode, Erika Hamilton, MD, FASCO, and Ian Krop, MD, PhD, discuss recent developments in the field of first-line therapy and maintenance treatment for patients with HER2-positive metastatic breast cancer, including the following: Trastuzumab deruxtecan plus pertuzumab as first-line therapy based on data from DESTINY-Breast09 Adding palbociclib to HP and ET as maintenance therapy for HR-positive/HER2-positive MBC, based on data from PATINA Adding tucatinib to HP as maintenance therapy for HER2-positive MBC, based on data from HER2CLIMB-05 Presenters:  Erika Hamilton, MD, FASCO Chief Development Officer, Late Phase Director, Breast Cancer Research Program Sarah Cannon Research Institute (SCRI) Nashville, Tennessee Ian Krop, MD, PhD Professor of Medicine, Yale School of Medicine Associate Cancer Center Director for Clinical Research Yale Cancer Center New Haven, Connecticut Content based on an online CME program supported by an educational grant from Pfizer. Link to full program: https://bit.ly/4esvN9x  Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Featuring a slide presentation and related discussion from Dr Seth Wander, including the following topics: Biological impact of clinically relevant biomarkers (eg, ESR1 mutations, PIK3CA/AKT1/PTEN alterations) (0:00) Methodologies for biomarker assessment in clinical practice: Tissue versus liquid biopsy (5:21) Methodologies for biomarker assessment in clinical practice: Novel platforms (13:56) Appropriate timing for assessment of ESR1 and PI3K pathway alterations (17:34) Evolving guidelines for routine biomarker evaluation (21:37) Implications of precision oncology clinical trials for future biomarker utility (25:07) Summary, key questions, future directions (33:09) CME information and select publications  

Featuring an interview with Dr Seth Wander, including the following topics: Deciding between liquid and tissue biopsy; role of epigenetics in oncogenic events (0:00) Potential role of thymidine kinase testing in monitoring response to therapy (4:56) Interpretation of next-generation sequencing testing; use of targeted therapy (10:59) Phase III lidERA Breast Cancer trial and its implications for the use of giredestrant (14:19) Interpreting plots from the Guardant360® test; future applications of circulating tumor DNA (19:07) Toxicity surrounding use of agents targeting the PAM signaling pathway; treatment for patients with PAM pathway alterations and ESR1 mutations (25:15) Potential role of artificial intelligence in profiling biomarkers; comparative efficacy of first- and later-line use of CDK inhibitors (30:26) Case: A woman in her mid 60s diagnosed with hormone receptor (HR)-positive, HER2-low metastatic breast cancer experiences disease progression after 5 years despite letrozole/ribociclib and is found to have ESR1 mutations, treated sequentially with elacestrant then trastuzumab deruxtecan (39:10) Case: A woman in her mid 50s who previously received treatment for localized disease develops progressive metastatic HR-positive, HER2-negative, PIK3CA-mutated breast cancer (45:31) Case: A woman in her late 70s with HR-positive, HER2-negative breast cancer who previously received treatment for localized disease is now diagnosed with progressive PTEN-deficient metastatic disease (51:36) Case: A woman in her early 70s with HR-positive, HER2-low metastatic breast cancer and bone metastases initially receives letrozole in combination with abemaciclib, then abemaciclib monotherapy (53:59) CME information and select publications

Dr Seth Wander from Massachusetts General Hospital in Boston discusses the role of biomarker assessment in the management of HR-positive metastatic breast cancer. CME information and select publications here.

Featuring perspectives from Dr Virginia F Borges and Dr Ian E Krop, including the following topics: Introduction: Biology of "Triple-Positive" Breast Cancer; Implications for Therapeutic Development (0:00) Cases from the GMO Survey (13:01) First-Line Therapy for Metastatic HER2-Positive Disease (20:01) Maintenance Therapy for HR-Positive, HER2-Positive Disease (30:03) Maintenance Therapy for HR-Negative, HER2-Positive Disease (46:30) Cases from the GMO Survey (50:00) CME information and select publications

Dr Virginia F Borges from the University of Colorado Anschutz Medical Campus in Aurora and Dr Ian E Krop from Yale Cancer Center in New Haven, Connecticut, review clinical research data and best practices guiding the selection of first-line and maintenance therapy for patients with ER-positive, HER2-positive metastatic breast cancer. CME information and select publications here.

In this podcast, experts Joyce O'Shaughnessy, MD; Reshma L. Mahtani, DO; Heather McArthur, MD, MPH; and Paolo Tarantino, MD, PhD; discuss results of recent frontline maintenance trials for patients with HER2-positive (HER2+) metastatic breast cancer (MBC) and their implications for treatment sequencing and patient management.

Reina Haque, PhD, MPH, discusses the link between antihypertensive treatment and survival in metastatic breast cancer.

Where do PI3K/AKT pathway inhibitors fit in the modern treatment landscape of breast cancer? Credit available for this activity expires: 3/19/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/clinical-perspectives-use-pi3k-akt-pathway-inhibitors-2026a100087h?ecd=bdc_podcast_libsyn_mscpedu

In this episode of the Oncology Brothers podcast, we were joined by two international experts — Professor Gary Tse, a pathologist from the Chinese University of Hong Kong, and Dr. Carlos Barrios, a medical oncologist from Brazil — to unpack the evolving landscape of HER2 testing in breast cancer. What was once a binary positive or negative classification has now expanded to include HER2-low and HER2-ultra-low, opening the door to new treatment options for the majority of breast cancer patients. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o   Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics discussed included: How HER2 classification has evolved from a binary result to a continuous spectrum including HER2-low and HER2-ultra-low, driven by the efficacy of antibody drug conjugates like T-DXd Pre-analytical challenges in metastatic settings including tumor heterogeneity The role of IHC, ISH, NGS, and liquid biopsy in HER2 assessment, and how each tool fits into clinical practice. The importance of multidisciplinary collaboration between pathologists and oncologists to ensure accurate interpretation and optimal treatment selection. Join us for this expert discussion on one of the most clinically impactful topics in breast oncology today. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology! #HER2, #BreastCancer, #BiomarkerTesting, #PrecisionOncology, #OncologyBrothers

After a short break, the podcast is back with a refreshed focus and format.In this episode, Heather shares why the podcast subtitle has changed to Real Conversations About Living with Metastatic Breast Cancer and what listeners can expect moving forward. Living with metastatic breast cancer is about much more than treatment. It touches work, relationships, finances, identity, energy, and the day-to-day realities of life with an incurable illness.This podcast is a space for honest conversations about those experiences — the hard parts, the meaningful parts, and the ways people continue building full lives while living alongside metastatic disease.Moving forward, the podcast will include a mix of:• Long-term survivor stories• Listener Q&A episodes• Caregiver conversations• Occasional expert guests• Solo episodes about the realities of living with metastatic breast cancerHeather was diagnosed with metastatic breast cancer at 26 and has now been living with the disease for more than 25 years. Through this podcast she shares perspective, lived experience, and conversations that help people navigate life with metastatic cancer.Sensational Survivor SeriesIf you have been living with metastatic breast cancer for 10 years or more and would like to share your story on the podcast, you can apply here:https://forms.gle/6H9K7NXMAeN1QEv87Listener QuestionsHave a question you'd like answered in a future episode? Submit it through the contact form:https://heatherjose.comConnect with HeatherInstagram: https://instagram.com/heatherbjoseWebsite: https://heatherjose.comMusicIntro and outro music for the podcast was created by Heather's son, Ty. You can find his music here:Instagram: https://instagram.com/tyjosee

Listen to learn from Sara M. Tolaney, MD, MPH, and Virginia Kaklamani, MD, DSc,  about new clinical trial data and updates informing the care of patients with early breast cancer and locally advanced/metastatic breast cancer that were presented at the 2025 San Antonio Breast Cancer Symposium. Presenters: Sara M. Tolaney, MD, MPH Chief, Division of Breast Oncology Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Virginia Kaklamani, MD, DSc Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment A.B. Alexander Distinguished Chair in Oncology Leader, Breast Oncology Program UT Health San Antonio MD Anderson Cancer Center San Antonio, Texas Link to full program:https://bit.ly/46Qv9OK Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?

Last week in Part 1, I shared the story of being diagnosed with metastatic (stage 4) breast cancer at just 26 years old — the shock, fear, and life-altering moment that changed everything.In Part 2, I talk about what came next.After living with metastatic disease for 27 years, my perspective on life, time, fear, and what truly matters has shifted in ways I never expected.This episode is about:• learning to live fully inside uncertainty• letting go of waiting for life to feel safe• naming the hard stuff without being consumed by it• and discovering meaning alongside ongoing treatmentIt's not about staying positive.It's about staying present.If you're living with cancer, loving someone who is, or navigating a season of life that feels uncertain or heavy, I hope this conversation reminds you that life can still be meaningful — even here.Available Now!

At 26 years old, I was diagnosed with metastatic (stage 4) breast cancer — a moment that changed everything in an instant.In Part 1 of my story, I share what led up to my diagnosis, the shock of hearing the words “stage four,” and what those early days of fear, uncertainty, and life-altering decisions were really like.This isn't a clinical cancer story.It's the human side — the emotions, the questions, the grief, and the beginning of learning how to live inside a life I never planned for.If you're newly diagnosed, supporting someone you love, or walking through something that feels overwhelming, this episode is for you.Part 2 will dive into how those early experiences shaped the way I live fully with metastatic disease today.Available Now!

In this beautifully hopeful episode, Wren, the creator of the Living Our Breast Lives Podcast, is joined by the incredible Metastatic Breast Cancer Thriver, Heather Jose, the MBC thriver living with triple positive metastatic breast cancer for 27 YEARS! Heather Jose is a long-term metastatic breast cancer thriver, advocate, and the host of the podcast I'm Still Here: Lessons from Life with Metastatic Breast Cancer. Diagnosed at 26 and living with metastatic disease for over 25 years, Heather focuses on honest, grounded conversations about what it means to live fully — not just survive — alongside breast cancer. After her diagnosis, Heather went on to adopt a child, redefining what building a family can look like after metastatic breast cancer and showing that life doesn't stop at a diagnosis, it evolves. She has spent decades navigating treatment, motherhood, advocacy, and survivorship, all while helping others feel less alone.Listen to this episode as it breaks down:Who is Heather Jose? – Meeting the woman behind the diagnosisHer MBC story – Diagnosed in 1998, her subtype, and how she's still here decades laterThen vs. now – What MBC treatment looked like then and how far it's comeStrength without the pressure – The moments that carried her through and why the term "inspirational" comes with a heavy weight to itLiving with grief and joy – Mourning the life imagined while fully living the one she hasMotherhood after MBC – Infertility, adoption, and expanding her family against the odds“I'm Still Here” – Why Heather launched her podcast and who it's forLong-term survivorship – What it really means and what she's still dreaming of for the future Living Our Breast Lives Information:Email: livingourbreastlivespodcast1@gmail.comInstagram: @livingourbreastlivesFounder: Wren MorrobelPersonal Instagram: @wren_morrPodcast Guest Speaker: Heather Jose's Information:Email: mail@heatherjose.comInstagram: @heatherbjoseFacebook: Heather JoseWebsite: www.heatherjose.comYouTube: I'm Still Here

In today's episode, the discussion features Komal Jhaveri, MD, FACP, a breast medical oncologist at Memorial Sloan Kettering Cancer Center, who reviewed the evolving role of TROP2-directed antibody–drug conjugates (ADCs) in the management of hormone receptor (HR)–positive, HER2-negative metastatic breast cancer. She drew on findings from the phase 3 ASCENT-07 trial (NCT05840211), which evaluated sacituzumab govitecan-hziy (Trodelvy) in the first-line setting following endocrine therapy for patients with HR-positive, HER2-negative metastatic breast cancer.In this exclusive interview, Dr Jhaveri discussed the rationale for evaluating sacituzumab govitecan earlier in the treatment paradigm, summarized key efficacy outcomes from ASCENT-07, and contextualized why the trial did not meet its primary progression-free survival end point. She also highlighted how disease biology and patient selection may influence outcomes when ADCs are moved into earlier lines of therapy, and outlined practical considerations for toxicity management and future trial design as the TROP2 ADC landscape continues to evolve.asts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Join Melissa Berry as she welcomes Annie Bond, metastatic breast cancer thriver, advocate, and comedian, to share her first-time experience at SABCS 2025. Together, they explore the moments, conversations, and insights that matter most for metastatic patients and advocates, focusing on advocacy, representation, and the power of patient voices. This episode highlights the urgent need for more data and research in metastatic breast cancer and shows how patient advocacy can drive meaningful change. As part of the "Your Guide to SABCS" series, produced with the Triple Negative Breast Cancer Foundation and TOUCH The Black Breast Cancer Alliance, this episode offers a patient-led perspective on SABCS, demonstrating that the conference is about more than science. It emphasizes advancing metastatic breast cancer research and elevating the voices of those living with the disease. Thank you to BioNtech, Lilly, Gilead, AstraZeneca and Pfizer for making this episode possible.

In this special episode of I'm Still Here, Heather sits down with her son Ty to talk openly about his adoption journey, growing up as a brown child in a rural community, and what it's been like navigating identity, belonging, and difference.Ty shares his story of being adopted from India, what family means when you don't share DNA, and the moments that shaped how he sees himself and the world. Together, they talk about racism, being pulled over, finding confidence, developing empathy, and how music became Ty's way of expressing his life experiences.This is an honest, real conversation about growing up different, learning to be comfortable in your own skin, and finding your people — even when it isn't easy.Available Now!

Eat This, Not That — 2026 EditionWhat do I actually eat — and how do I think about food now?In this episode, Heather shares her Eat This, Not That — 2026 Edition, responding to one of the most common questions she gets. This is not about food rules, trends, or government guidelines — it's about real food, real life, and what helps her feel steady and energized while living with metastatic breast cancer.In this conversation, Heather talks about:Why she doesn't follow nutrition rules (even when new guidelines come out)The simple framework she uses instead: protein, fiber, and varietyEating real food, mostly plants — without rigidityConsistency over optimizationUsing ideas like “30 plants a week” as a gentle nudge, not a mandateLetting food support your life — not become another thing to manageThis episode is honest, practical, and grounded in lived experience — not extremes.Need a quick reset when life feels overwhelming?Heather's 15-minute guide, Break the Cancer Spiral, helps you steady your mindset anytime things start to spin.

In this podcast, experts William J. Gradishar, MD, FASCO, FACP; Stephanie L. Graff, MD, FACP, FASCO; and Cynthia X. Ma, MD, PhD; discuss current and emerging therapeutic options, including next-generation endocrine therapies, to target the estrogen receptor signaling pathway for the treatment of hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (MBC).

While cleaning and decluttering, Heather came across a stack of books that carried her through the early years of living with cancer. Some were informational. Some were inspirational. And some simply helped her feel seen.In this episode, Heather and Larry talk through those books—not as prescriptions or promises, but as companions during a time when reaching for anything steady mattered. They reflect on why certain voices, stories, and practices were helpful, how repetition and slowing down supported Heather's mindset, and how mental and emotional care became just as important as physical treatment.The conversation then expands into what building a “library” looks like today. Not just books—but audio, YouTube, meditation, journaling, saved resources, and non-cancer content that helps regulate fear, doubt, and overwhelm. Heather shares how she now thinks about choosing resources that feel safe, grounding, and accessible—and why what helps can (and should) change over time.This episode is an honest look at what it means to feed your mind with care, build a personal support library, and give yourself permission to reach for whatever helps you feel a little more steady.If you have books, videos, or resources that have helped you through a hard season, Heather invites you to share them—so we can help each other build libraries that hold us.Available Now!

A new year often comes with pressure to set goals, do more, and fix ourselves. But when you're living with metastatic breast cancer, that framework can feel exhausting — and disconnected from reality.In this New Year episode, we talk about a different way forward. One that starts by asking a more honest question:What do I need this year?Because when cancer doesn't reset on January 1st, the goal isn't reinvention — it's living.We explore:Why living with metastatic breast cancer is already enoughLetting go of “shoulds” and redefining progressShifting from performance to presenceCreating anchors instead of rigid routinesTrusting what your body and life are asking for right nowWhy rest matters — and why engagement still does tooThis is an honest, grounded conversation about living well with metastatic disease — without pretending it's easy, and without waiting for life to begin “after.”You're not behind.You're not broken.And you don't need to fix yourself to deserve a meaningful life.Living is the goal.